PRP therapy is often presented as a straightforward regenerative treatment: take a small blood sample, concentrate the platelets, and return them to the tissue requiring support. Clinically, the reality is more exacting. The quality of the assessment, the preparation method, the injection technique and the indication all influence whether platelet-rich plasma is likely to offer meaningful benefit.
For patients, PRP can be an appealing option because it uses an autologous material rather than a synthetic implant or manufactured filler. For clinicians, it requires a disciplined understanding of wound biology, tissue anatomy, realistic endpoints and informed consent. It should not be treated as a generic injectable, nor as a substitute for diagnosis.
What PRP therapy is designed to do
Platelet-rich plasma is produced by processing a patient’s own blood to create a plasma fraction with a platelet concentration above baseline. Platelets contain signalling proteins and growth factors involved in haemostasis, inflammation and tissue repair. When introduced into an appropriate clinical environment, PRP may help modulate healing responses and support remodelling within skin, scalp, musculoskeletal structures or surgical tissues.
This biological rationale is persuasive, but it does not mean that every tissue concern will respond in the same way. Platelets do not simply create new collagen, reverse advanced disease or restore severely depleted tissue architecture. Their role is better understood as one component of a carefully selected regenerative strategy, where the objective is to improve the conditions for repair rather than promise a predetermined cosmetic result.
In aesthetic medicine, PRP is commonly considered for skin quality, photoageing, crepey texture, selected acne scarring protocols and hair thinning. It may also be used alongside other treatments where there is a sound clinical reason to support healing or recovery. The indication must lead the plan, not the availability of the technology.
Why the evidence requires careful reading
PRP therapy has been studied across several specialties, but the literature is heterogeneous. Studies differ in platelet concentration, white-cell content, activation method, injection depth, treatment intervals and the outcome measures used. A positive result with one preparation system or patient cohort cannot automatically be transferred to another.
The evidence base is particularly encouraging in some areas of androgenetic alopecia, where repeated scalp PRP treatments may improve hair density or reduce shedding for appropriately selected patients. Results are variable, and PRP is not a cure for patterned hair loss. It may be more valuable when introduced early, combined with evidence-based medical management where suitable, and reviewed with standardised photography and realistic timeframes.
For facial rejuvenation, the strongest case is often for gradual improvement in skin quality rather than dramatic lifting or volumisation. Patients concerned with fine lines, dullness, superficial texture changes or reduced dermal resilience may be suitable candidates. A patient seeking immediate correction of significant volume loss, advanced laxity or deep static folds requires a different conversation and potentially a different treatment pathway.
Research into PRP for scarring and post-procedural healing remains promising, particularly when used as part of a wider protocol. Yet promise is not equivalence. Clinicians should distinguish between biological plausibility, early clinical experience and high-quality comparative evidence. This protects patients from exaggerated claims and protects the discipline from becoming driven by fashion rather than standards.
Preparation is not a minor technical detail
The term PRP describes a category, not one uniform product. Variations in centrifugation, collection systems and processing can change the cellular composition of the final preparation. Some protocols aim for leucocyte-poor PRP, while others incorporate leucocytes for specific clinical purposes. The appropriate choice depends on the tissue being treated and the intended biological response.
Platelet concentration also matters, although more is not automatically better. Excessive concentration, inappropriate activation or poor handling may affect the clinical behaviour of the preparation. Timing is equally relevant. Once blood has been collected and processed, the product should be used according to validated protocol and under appropriate aseptic conditions.
For this reason, clinics should be able to account for their method. A defensible protocol includes the device used, blood volume collected, centrifugation parameters, intended product characteristics, treatment plane, number of sessions and post-treatment guidance. Documentation is not administrative excess. It is central to reproducibility, audit and patient safety.
Patient selection determines much of the outcome
The most sophisticated preparation technique cannot overcome unsuitable selection. A consultation should establish the patient’s diagnosis, medical history, medications, nutritional status, smoking history, previous procedures and expectations. In hair loss, for example, it is essential to identify whether the cause is androgenetic alopecia, telogen effluvium, inflammatory scalp disease, nutritional deficiency, medication-related shedding or another condition requiring medical investigation.
Similarly, skin quality concerns may be influenced by ultraviolet exposure, active inflammatory disease, rosacea, pigmentary disorders, hormonal change or poorly controlled systemic illness. PRP may have a place, but it should not obscure the need to treat the underlying driver.
Caution or deferral may be appropriate for patients with active infection at the treatment site, certain platelet disorders, significant coagulation abnormalities, uncontrolled systemic disease or unrealistic expectations. Anticoagulant and antiplatelet medicines require particular consideration. A patient should never alter prescribed medication solely to facilitate an aesthetic procedure without discussion with the clinician responsible for that medication.
Safe injection practice remains non-negotiable
Although PRP is autologous, it is not risk-free. Venepuncture and injection carry familiar procedural risks including bruising, pain, swelling, infection and inflammatory reactions. Scalp treatments may cause temporary tenderness or headache. Facial treatments demand the same anatomical knowledge, aseptic discipline and complication awareness expected of any injectable procedure.
The treatment environment matters. Appropriate consent, clinical photography, emergency preparedness, sharps safety and clear aftercare should form part of routine practice. Patients should understand that short-term redness, swelling and bruising can occur, and that results, when they occur, are generally progressive rather than immediate.
A responsible practitioner also knows when not to combine treatments. Combining PRP with microneedling, lasers, energy-based devices or other injectables may be appropriate in selected protocols, but combination therapy can also make it difficult to identify the source of an adverse event or assess which element produced the improvement. Staged treatment plans are sometimes clinically wiser than an aggressively layered approach.
Measuring outcomes beyond patient enthusiasm
Regenerative procedures can be especially vulnerable to subjective reporting. A patient may feel that their skin is fresher, but clinical practice should seek more than an early impression. Baseline and follow-up photographs taken with consistent lighting, position and camera settings are valuable. In hair restoration, standardised parting, hair length and imaging intervals make a material difference to interpretation.
Outcome measures should reflect the indication. Skin protocols may assess texture, hydration, fine rhytides and patient-reported satisfaction. Hair protocols may assess shedding, density, calibre and photographic change over several months. Where a treatment has not met its intended endpoint, clinicians should be prepared to reassess the diagnosis or recommend discontinuation rather than repeatedly extending a protocol without benefit.
This is where medical leadership differs from procedure-led commerce. The aim is not to sell a course of treatments. It is to make a justified recommendation, review the response honestly and preserve long-term tissue health.
A regenerative treatment, not a regenerative claim
PRP has earned a legitimate place within modern regenerative and aesthetic medicine, particularly when used with technical consistency and clear clinical purpose. It is neither a miracle intervention nor a passing novelty. Its value lies in careful application: matching a biologically active preparation to a patient whose condition, expectations and treatment plan make sense.
Professor Patrick Treacy’s work in regenerative aesthetics has consistently emphasised that innovation must develop alongside education, evidence and patient-safety protocols. That principle is especially relevant to PRP, where enthusiasm can easily outpace standardisation.
For patients and practitioners alike, the most useful question is not whether PRP is good or bad. It is whether this particular protocol, for this particular indication, is justified by diagnosis, evidence and the standard of care. That is the foundation on which credible regenerative medicine should continue to progress.